IGC appoints Claudia Grimaldi to Board as non-independent director

IGC Pharma, Inc.

Claudia Grimaldi appointed to the Board as non-independent director, effective March 23, 2022.
Board now has 5 directors, majority independent; Grimaldi currently VP, Principal Finance Officer, and CCO.
Grimaldi's employment agreement provides $150K base salary, benefits, and 18-month severance on termination without cause.
She also serves as Managing Director of Hamsa Biochem SAS (Colombia subsidiary) and director of India subsidiary.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Claudia Grimaldi

Director

IGC · IGC Pharma, Inc.

Effective: 2022-03-23
Filed: March 23, 2022, 7:59 PM ET

On March 23, 2022, the Board of Directors (the “Board”) of India Globalization Capital Inc. (the “Company” “IGC” or “we”) appointed Ms. Claudia Grimaldi (“Ms. Grimaldi”) to serve on the Board as a non-independent director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Claudia Grimaldi was appointed as Director at IGC Pharma, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 23, 2022, the Board of Directors (the “Board”) of India Globalization Capital Inc. (the “Company” “IGC” or “we”) appointed Ms. Claudia Grimaldi (“Ms. Grimaldi”) to serve on the Board as a non-independent director.

View on SEC.gov

IGC Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001185185-22-000312

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.